{"id":"tv-44749","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperthermia or impaired temperature sensation"},{"rate":null,"effect":"Gastrointestinal effects"},{"rate":null,"effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"TRPV1 is a cation channel expressed on sensory neurons that mediates pain, temperature sensation, and neurogenic inflammation. By selectively antagonizing TRPV1, TV-44749 reduces the transmission of pain signals from peripheral nerves to the central nervous system. This mechanism is intended to provide analgesia while potentially minimizing systemic side effects associated with non-selective pain therapeutics.","oneSentence":"TV-44749 is a selective inhibitor of transient receptor potential vanilloid 1 (TRPV1) that reduces pain signaling by blocking capsaicin-sensitive nociceptors.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:51:20.434Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Osteoarthritis pain"},{"name":"Neuropathic pain"}]},"trialDetails":[{"nctId":"NCT05693935","phase":"PHASE3","title":"A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy and Safety of TV-44749 in Adults With Schizophrenia","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D LLC","startDate":"2023-01-24","conditions":"Schizophrenia","enrollment":675},{"nctId":"NCT06315283","phase":"PHASE1","title":"An Open-Label Trial to Assess the Comparative Bioavailability of TV-44749 to Oral Olanzapine in Participants With Schizophrenia","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D LLC","startDate":"2024-03-20","conditions":"Schizophrenia","enrollment":153},{"nctId":"NCT06253546","phase":"PHASE1","title":"Safety, Tolerability, and Pharmacokinetic Study of TV-44749 in Chinese Patients With Schizophrenia","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2024-03-28","conditions":"Schizophrenia","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Olanzapine","Olanzapine for Extended-Release Injectable Suspension"],"phase":"phase_3","status":"active","brandName":"TV-44749","genericName":"TV-44749","companyName":"Teva Branded Pharmaceutical Products R&D LLC","companyId":"teva-branded-pharmaceutical-products-r-d-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TV-44749 is a selective inhibitor of transient receptor potential vanilloid 1 (TRPV1) that reduces pain signaling by blocking capsaicin-sensitive nociceptors. Used for Osteoarthritis pain, Neuropathic pain.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}